Journals / Eurasian Journal of Medical Investigation / 2019 / Cilt: 3 - Sayı: 3

Microorganisms Causing Ventilator-Associated Pneumonia and Their Antibiotic Susceptibility

Pages
227–231
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The fact that Acinetobacter spp., which is resistantto carbapenems, quinolones, piperacillin-tazobactam and cephalosporins, was the most common agent in VAP, cansignifiantly affct the mortality rate of the infection

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of this study was to determine the microorganisms causing ventilator-associated pneumonia(VAP) and investigate their antibiotic susceptibility.Methods: Patients diagnosed with VAP in the adult intensive care units (ICUs) between January 2015 and December2018 were included in the study.
📊
Key Findings & Data:VITEK 2 (bioMérieux, Marcy l’Etoile, France) automated microbiology system was usedto identify microorganisms and to determine their antibiotic susceptibility.Results: Average VAP rates was found 26.51 per 1000 ventilator-days.
💡
Conclusion & Impact:The fact that Acinetobacter spp., which is resistantto carbapenems, quinolones, piperacillin-tazobactam and cephalosporins, was the most common agent in VAP, cansignifiantly affct the mortality rate of the infection
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of this study was to determine the microorganisms causing ventilator-associated pneumonia(VAP) and investigate their antibiotic susceptibility.Methods: Patients diagnosed with VAP in the adult intensive care units (ICUs) between January 2015 and December2018 were included in the study. VITEK 2 (bioMérieux, Marcy l’Etoile, France) automated microbiology system was usedto identify microorganisms and to determine their antibiotic susceptibility.Results: Average VAP rates was found 26.51 per 1000 ventilator-days. A single microorganism was isolated in 104 ofa total of 105 patients while two microorganisms were isolated in 1 patient. Of the isolated microorganisms, 94.3%(n=100) were Gram-negative bacteria and 5.7% (n=6) were Gram-positive bacteria. When the distribution of all microorganisms is examined in order of frequency, 62.2% were found to be Acinetobacter spp., 17.9% Pseudomonas spp., 6.6%Klebsiella pneumoniae, 4.7% Staphylococcus aureus, 3.7% Serratia marcescens, 2.8% Escherichia coli, 0.9% Enterococcusfaecium, and 0.9% Stenotrophomonas maltophilia. The most effctive antibiotics against Acinetobacter spp. were foundto be colistin (96.9%), tigecycline (95%), amikacin (15%) and gentamicin (5%), whereas those the most effctive againstPseudomonas spp. were found to be colistin (94.1%), ceftazidime (57.8%), gentamicin (55.5%), ciproflxacin (50%), amikacin(50%), and piperacillin/tazobactam (42.1%).Conclusion: Acinetobacter spp. was the most common agent in VAP. The fact that Acinetobacter spp., which is resistantto carbapenems, quinolones, piperacillin-tazobactam and cephalosporins, was the most common agent in VAP, cansignifiantly affct the mortality rate of the infection

🔖

Cite This Article

KARAKEÇİLİ, F., ÜNVER, E., ÇIKMAN, A., BİNAY, U. D., KOÇ, A., KARAVAŞ, E. (2022). Microorganisms Causing Ventilator-Associated Pneumonia and Their Antibiotic Susceptibility. Eurasian Journal of Medical Investigation, Cilt: 3 - Sayı: 3, 227–231. https://ajindex.com/articles/508738

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Spalding MC, Cripps MW, Minshall CT. Ventilator-Associated Pneumonia: New Defiitions. Crit Care Clin 2017;33:277–92
  2. Cikman A, Gulhan B, Aydin M, Ceylan MR, Parlak M, Karakecili F, et al. In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia. Int J Med Sci 2015;12:695–700. [CrossRef] 3. Karasu D, Yılmaz C, Durmuş G, Özer D, Çağlayan Ü, Karaduman İ, et al. Evaluation of Healthcare-Associated Infections in Critically Ill Patients Receiving Long-Term Treatment in the Intensive Care Unit. Klimik Derg 2016;29:72–7. [CrossRef] 4. Mietto C, Pinciroli R, Patel N, Berra L. Ventilator associated pneumonia: evolving defiitions and preventive strategies. Respir Care 2013;58:990–1007. [CrossRef] 5. Li Bassi G, Senussi T, Aguilera Xiol E. Prevention of ventilatorassociated pneumonia. Curr Opin Infect Dis 2017;30:214–20
  3. Tağrıkulu H, Memiş D, İnal MT, Turan N. Investigation of Ventilator Associated Pneumoniae in Intensive Care Patients. J Turk Soc Intens Care 2016;14:28–38. [CrossRef] 7. Meyancı G, Öz H, Mamal Torun M. Ventilatory-associated pneumonia. Cerrahpaşa J Med 1999;30:214–20
  4. Sağmak-Tartar A, Özer AB, Ulu R, Akbulut A. Microbiological Evaluation of the Pathogens Isolated From the Endotracheal Aspirate Samples of the Patients Followed in the Intensive Care Units: A One-Year Retrospective Analysis. Klinik Derg 2018; 31:56–60. [CrossRef] 9. Bassetti M, Taramaso L, Giacobbe DR, Pelosi P. Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti Infect Ther 2012; 10:585–96. [CrossRef] 10. Houck PM, Bratzler DW, Nsa W, Ma A, Barlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637–44. [CrossRef] 11. CLSI (2012). Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 22nd informational Supplement. Document M100-S22. Wayne, PA;2012
  5. EUCAST (2016). European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. EUCAST document version 6.0, 2016
  6. Bilici A, Karahocagil MK, Yapıcı K, Göktaş U, Yaman G, Katı İ, et al. Ventilator Associated Pneumonia: Incidence, Risk Factors, and causative agents. Van Tıp Derg 2012;19:170–6
  7. Rumbak MJ. Pneumonia in patients